-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $1.5

Benzinga·05/11/2026 13:46:35
Listen to the news
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1 to $1.5.